WaveMan
WaveMan · Company
QCLS · Q/C Technologies, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

QCLS Q/c Technologies (QCLS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · In vitro & in vivo diagnostic substances · CIK 0001321834
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
12
13F, latest reported quarter

Q/c Technologies insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Q/C TECHNOLOGIES, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Voss Chelsea Sierra
Director
BUY
2026-05-14 SECtraded 2026-03-30
1,753
$5.5K
-89.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 2.8% of the 61,555 shares held after it.
  • No other insider bought within 30 days.
  • 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Voss Chelsea Sierra bought about $5.5K of QCLS on Mar 30, 2026, the largest insider purchase at the company on our record; 12 funds added in the latest 13F quarter.
1 transaction on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
12 funds bought in last quarter
below 79% of Pharma & Biotech
Revenue
-5.3% year over year
below 62% of Pharma & Biotech
Margin
-737.3% net margin
below 82% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
12.6% of the float short (float per yahoo 2026-10-27) · 3.6 days to cover · settled 2026-10-15
more than 79% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch QCLS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-89.0%12M
-89%-37%+16%+69%2025-102025-122026-022026-042026-062026-082026-10 2026-03-30 · Voss Chelsea Sierra bought $5.5K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns QCLS: institutional holders (13F)

13F holdings, latest reported quarter
Quinn Opportunity Partners LLC
123,024 sh
$479.8K
VANGUARD CAPITAL MANAGEMENT LLC
115,031 sh
$448.6K
JANE STREET GROUP, LLC
87,241 sh
$340.2K
GEODE CAPITAL MANAGEMENT, LLC
70,682 sh
$275.7K
UBS Group AG
58,894 sh
$229.7K

Congress trades in QCLS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

QCLS planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

QCLS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
VANGUARD EXTENDED MARKET INDEX FUND
$448.6K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$102.1K position · as of 2026-05-31
0.0%
U.S. SMALL CAP PORTFOLIO
$34.4K position · as of 2026-07-31
0.0%
Dimensional U.S. Small Cap ETF
$14.5K position · as of 2026-07-31
0.0%
Total Stock Market Index Trust
$757 position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$12.9K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Dr. Christopher Chapman
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$2.9M
n/a
$444.8K
+95%
n/a
2022
$261.8K
n/a
$234.7K
-71%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 12 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

QCLS financials

Revenue growth
-5.3%
XBRL, annual
Net margin
-737.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$862.0K
four quarters, 2019-07-01 to 2020-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-155.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-82.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-91.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
0.17x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$9.8M-$10.2M-$17.1M-$15.3M
Net income-$11.6M-$23.4M-$4.0M-$15.2M
EPS (diluted)-8.66-1,080.87-5.33-11.74
Operating cash flow-$9.1M-$9.0M-$13.0M-$12.3M
Cash$987.0K$173.2K$2.7M$749.1K
SEC XBRL, fiscal years, as known on 2026-10-28

QCLS Stock Sonar score 4/7 axes

Find similar shapesCompare

QCLS ranks highest on growth (38th percentile) and profitability (26th), and lowest on risk and compliance (17th), among Pharma & Biotech peers.

Profitability
26
Inputs
  • Return on equity-155.0% · 22 pct, sector of 545
  • Return on assets-82.8% · 29 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-91.6% · 29 pct, sector of 576
Growth
38
Inputs
  • Revenue growth, YoY-5.3% · 38 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
21
Inputs
  • Funds adding, latest quarter12 · 21 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
17
Inputs
  • Short interest, % of float+12.6% · 31 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+50.5% · 4 pct, sector of 511
3 not measured: Financial health, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies